Physician profile
Erin Dodson
NPI 1346661428
$823.98
in general payments reported to CMS, 2019-2025
15 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $422 · 2024: $93.71 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $402.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.42 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $203.30 | 2022-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $45.32 | 2022-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.91 | 2024-2025 | Xifaxan |
| Boston Scientific Corporation | $39.80 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.05 | 2024-2025 | Caplyta |
| Beta Bionics, INC. | $33.89 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $19.41 | 2022 | |
| Corcept Therapeutics | $15.86 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $14.89 | 2025 | Zoryve |
| Astellas Pharma US INC | $14.89 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $14.20 | 2025 | Gardasil 9, Enflonsia, Capvaxive |
| Amgen INC. | $14.05 | 2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $13.44 | 2024 | Trelegy Ellipta |
| Hologic Sales and Service, LLC | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Dodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.